Skip to content

Ultrasound and Functional Thyroid Evaluation

Ultrasound and Functional Thyroid Evaluation in Preterm Infants Born Between 24 and 32 Weeks of Gestation

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04208503
Enrollment
200
Registered
2019-12-23
Start date
2019-12-19
Completion date
2021-12-31
Last updated
2021-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gland; Functional Disturbance, Thyroid

Keywords

thyroid volume, ultrasound, preterm infants, thyroid hormone

Brief summary

Thyroid disorders are most commonly concomitant with prematurity and still remains a controversial topic. The incidence of a temporary form of hypothyroidism among preterm neonates is higher than in the general population. Transient prematurity hypothyroxinemia is defined as a temporary reduction in FT4 values without increase in TSH values. Currently, there is no consensus about normal thyrotropine (TSH) and free thyroxine (FT4) values in preterm infants. The aim of this study is to determine the volume of the thyroid gland in preterm infants born between 24 and 32 weeks of gestation inborn or admitted to the unit within 14 days from birth and compare it with the results of TSH and FT4 blood concentration. Besides, the objective of the study is to determine values of thyroid hormones in premature infants born before 33 wk gestation to help neonatologist to interpreter the thyroid hormone results

Detailed description

Thyroid disorders are most commonly concomitant with prematurity and still remains a controversial topic. Preterm infants are susceptible to thyroid disorders due to many reasons including immaturity of hypothalamopituitary-thyroid axis, non-thyroidal illness, impaired synthesis and metabolism of thyroid hormones, medication administration like dopamine, steroids, caffeine.The incidence of a temporary form of hypothyroidism among preterm neonates is higher than in the general population. Transient prematurity hypothyroxinemia is defined as a temporary reduction in FT4 values without increase in TSH values. It is a diagnostic challenge in order to differentiate it from thyroid disfunction in the critically ill patient. Currently, there is no consensus about normal thyrotropine (TSH) and free thyroxine (FT4) values in preterm infants. Given the delayed appearance of TSH value increase in preterm newborns additional thyroid evaluation methods are sought. We believe the thyroid ultrasound might prove helpful. The aim of this study is to determine the volume of the thyroid gland in preterm infants born between 24 and 32 weeks of gestation inborn or admitted to the unit within 14 days from birth and compare it with the results of TSH and FT4 blood concentration. We will performed the thyroid ultrasound to estimate the thyroid volume to aid in the comparative evaluation of infants with suspected thyroid disease. The value of sonography thyroid volume will give specialists possibility to identify a gland as normal, small or enlarged. Besides, the objective of the study is to determine value of thyroid hormones in premature infants born before 33 wk gestation to help neonatologist to interpreter the thyroid hormone results

Interventions

DIAGNOSTIC_TESTthyroid ultrasound

After meeting enrolment criteria the thyroid ultrasound will be performed at 32 and 36 weeks of gestation, blood test for TSH and FT4 will be obtained at 14-21 day of life, at 32 and 36 weeks of gestation

Sponsors

Princess Anna Mazowiecka Hospital, Warsaw, Poland
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Weeks to 12 Weeks
Healthy volunteers
Yes

Inclusion criteria

* preterm infants born between 24 and 32 weeks of gestation (estimated by ultrasound) * in born or admitted to the unit within one week from birth * randomization within 7 days from birth * parental consent

Exclusion criteria

* preterm delivery \<23 weeks of gestation or \> 32 weeks (estimated by ultrasound) * major congenital abnormalities * no parental consent * medications used after birth: steroids, vasopressors (up to 12 hours after end of treatment) * positive thyroid stimulating antibodies (TSAb) in the mother * mothers with thyroid disease treated with antythyroid drugs * mothers treated with amiodarone

Design outcomes

Primary

MeasureTime frameDescription
Determination of FT4 and TSH values in preterm infants born at 24-28 weeks of gestation14-21 days of life, at 32 and 36 weeks of PCAFT4 and TSH - blood concentration
Determination of FT4 and TSH values in preterm infants born at 29-32 weeks of gestationat 14-21 day of life, at 32 and 36 weeks of PCAFT4 and TSH - blood concentration
Determination of ultrasound thyroid volume in both groups of preterm infants (i.e., those born at 24-28 weeks of gestation and those born at 29-32 weeks of gestation)at 32 and 36 weeks of PCAThe thyroid volume
Evaluation of correlations between circulating thyroid hormone concentrations and thyroid volumeat 32 and 36 weeks of PCAcomparison of values of FT4, TSH and thyroid volume

Secondary

MeasureTime frameDescription
Comparison of changes in FT4 evaluated at 32 and 36 weeks of PCA in each group of preterm infantsat 14-21 day of life, at 32 and 36 weeks of PCAcomparison of results
Evaluation of the correlation between thyroid volume and circulating thyroid hormone concentrations with the head circumference and body mass at 32 and 36 weeks of PCAat 32 and 36 weeks of PCAcorrelation of results with the body mass and the head circumference
Comparison of changes in TSH evaluated at 32 and 36 weeks of PCA in each group of preterm infants14-21 days of life, at 32 and 36 weeks of PCAcomparison of results
Analysis of TSH values over time (to determine the optimal time for TSH measurement)at 14-21 day of life, at 32 and 36 weeks of PCAIntervention time
Evaluation of changes in ultrasound thyroid volume examined at 32 and 36 weeks of PCA in each group of preterm infantsat 32 and 36 weeks of PCAcomparison of results

Countries

Poland

Contacts

Primary ContactAleksandra Mikolajczak, MD PhD
aamikolajczak@wp.pl+48 603 440 112
Backup ContactRenata Bokiniec, Prof MD P
r.bokiniec@wp.pl+48 22 59 66 155

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026